Gilead Sciences: The Market May Be Underestimating Its Growth (Upgrade) (GILD)
· seekingalpha.com
Gilead’s 2026 outlook improves as R&D pipeline accelerates and Biktarvy & Livdelzi sales rise, lifting guidance.
Six days ago, on August 4, Gilead Sciences ( GILD ) released its Q2 earnings report. It showed higher sales growth rates for its HIV franchise, Livdelzi, and Tr...